Study of a new drug for multiple myeloma that has returned or not responded
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a new drug called QI-019B for people with multiple myeloma whose cancer has come back or stopped responding to other treatments. The goal is to see if it is safe and can help shrink or slow the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have multiple myeloma that has progressed after at least 2 prior treatments.
- You must have measurable signs of myeloma (like certain protein levels in blood or urine).
- You must be generally active and able to care for yourself (ECOG 0-2).
- Your blood counts (like white cells, red cells, platelets) must be within certain limits.
- Your kidney, liver, heart, and lung function must be adequate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new experimental drug called CM336 for people with multiple myeloma that has come back or stopped responding to standard treatments. The drug may work by helping your immune system attack and destroy myeloma cells. If you join, you will receive the study treatment and be closely monitored to see how well it works and how safe it is.
This trial tests a new treatment combination for multiple myeloma that has returned or stopped responding to previous therapy and has spread outside the bone marrow. It aims to see if the combination can shrink these tumors and improve outcomes.
This trial tests a new drug called QI-019A for people whose multiple myeloma has returned or stopped responding to at least two prior treatments. The goal is to see if it is safe and if it can help control the disease.
This study tests an experimental drug called RN9101 for people with multiple myeloma that has returned or stopped responding to other treatments. The drug targets a protein called BCMA found on myeloma cells, and the goal is to see if it is safe and can help control the disease.
This trial tests an experimental drug called QLS4131 for people whose multiple myeloma has come back or stopped responding to treatment. The goal is to see if the drug can help control the cancer.
This study tests an investigational drug for people with multiple myeloma, a type of blood cancer. It aims to see how safe and effective the treatment is for patients who are newly diagnosed or have relapsed after prior therapy.
Hear when a new Multiple Myeloma (MM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.